Efficacy and Safety of Intravenous Thrombolysis on Acute Branch Atheromatous Disease: A Retrospective Case-Control Study

Xiangbo Wu, Yang Liu, Chuang Nie, Zhiming Kang, Qunfeng Wang, Dong Sun, Huagang Li, Yumin Liu, Bin Mei, Xiangbo Wu, Yang Liu, Chuang Nie, Zhiming Kang, Qunfeng Wang, Dong Sun, Huagang Li, Yumin Liu, Bin Mei

Abstract

Background and Objective: Branch atheromatous disease (BAD) is distinctive from large-artery atherosclerosis and small-vessel disease, which is single subcortical infarction caused by the occlusion of perforator's orifice. This study aimed to indicate whether intravenous thrombolysis (IVT) with alteplase could prevent early neurological deterioration (END) and improve functional outcome for patients with BAD within 4.5 h after symptom onset. Methods: We retrospectively analyzed data collected from patients with BAD who were admitted to our hospital from January 2015 to August 2019. To investigate the efficacy and safety of IVT, subjects were classified into alteplase and control groups. A propensity score matching analysis was performed to control substantial heterogeneity of subgroup. The coprimary outcomes were END that is defined as an increase of ≥2 points in the National Institutes of Health Stroke Scale (NIHSS) score within 7 days after stroke, and favorable outcome at 3 months after stroke that defined by a score of 0-1 point on the modified Rankin scale (mRS). Results: A total of 135 patients were eventually enrolled in this study (n = 51 for the alteplase group and n = 84 for the control group). Additionally, 42 pairs of subjects were successfully matched by propensity score matching. Intravenous alteplase within 4.5 h after stroke onset reduced the incidence of END [unadjusted odds ratio (OR), 3.32; 95% confidence interval (CI), 1.06-10.37] and improved the clinical outcome at 3 months after stroke, with more patients achieving favorable functional prognosis (mRS, 0-1 point; unadjusted OR, 0.25; 95% CI, 0.10-0.62). Patients in the alteplase group were more likely to be independent (mRS, 0-2 points) at 3 months after stroke (unadjusted OR, 0.33; 95% CI, 0.12-0.90). The rate of death or dependence (mRS, ≥4 points) in the alteplase group was also markedly lower than that in the control group (unadjusted OR, 4.06; 95% CI, 1.03-16.02). Conclusion: Our findings indicated that intravenous thrombolysis may be a safe and effective therapy for patients with BAD.

Keywords: acute stroke; antiplatelet treatment; branch atheromatous disease; early neurological deterioration; intravenous thrombolysis; propensity score matching.

Copyright © 2020 Wu, Liu, Nie, Kang, Wang, Sun, Li, Liu and Mei.

Figures

Figure 1
Figure 1
Flowchart of selection of eligible study subjects. BAD, branch atheromatous disease.
Figure 2
Figure 2
Examples of cases with branch atheromatous disease (BAD). Case 1: A 57-year-old woman with right-sided weakness. (A) Diffusion-weighted imaging (DWI) showing cerebral stroke in the area of lenticulostriate artery. (B) Magnetic resonance angiography (MRA) illustrating no significant stenosis of parent artery. Case 2: A 61-year-old man with right-sided weakness and dysarthria. (C) DWI showing infarction extended to the ventral pontine surface in the area of paramedian pontine artery. (D) Vessel wall magnetic resonance imaging (VWMRI) depicting junctional plaque in the orifice of paramedian pontine artery. (E) MRA displaying no significant stenosis of basilar artery.
Figure 3
Figure 3
The distribution of scores on the modified Rankin scale (mRS) at 3 months after stroke was in favor of intravenous thrombolysis. The mRS scores ranged from 0 to 6, in which higher scores indicated more severe disability.

References

    1. Nah HW, Kang DW, Kwon SU, Kim JS. Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis. Stroke. (2010) 41:2822–7. 10.1161/STROKEAHA.110.599464
    1. Ryoo S, Lee MJ, Cha J, Jeon P, Bang OY. Differential vascular pathophysiologic types of intracranial atherosclerotic stroke: a high-resolution wall magnetic resonance imaging study. Stroke. (2015) 46:2815–21. 10.1161/STROKEAHA.115.010894
    1. Nakase T, Yoshioka S, Sasaki M, Suzuki A. Clinical evaluation of lacunar infarction and branch atheromatous disease. J Stroke Cerebrovasc Dis. (2013) 22:406–12. 10.1016/j.jstrokecerebrovasdis.2011.10.005
    1. Kwan MW, Mak W, Cheung RT, Ho SL. Ischemic stroke related to intracranial branch atheromatous disease and comparison with large and small artery diseases. J Neurol Sci. (2011) 303:80–4. 10.1016/j.jns.2011.01.008
    1. Fisher CM. Lacunes: Small, deep cerebral infarcts. Neurology. (1998) 50:841. 10.1212/WNL.50.4.841-a
    1. Yamamoto Y, Ohara T, Hamanaka M, Hosomi A, Tamura A, Akiguchi I. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. J Neurol Sci. (2011) 304:78–82. 10.1016/j.jns.2011.02.006
    1. Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ. Neuroimaging markers for early neurologic deterioration in single small subcortical infarction. Stroke. (2015) 46:687–91. 10.1161/STROKEAHA.114.007466
    1. Miyamoto N, Tanaka Y, Ueno Y, Kawamura M, Shimada Y, Tanaka R, et al. . Demographic, clinical, and radiologic predictors of neurologic deterioration in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. (2013) 22:205–10. 10.1016/j.jstrokecerebrovasdis.2011.07.018
    1. Group NIoNDaSr-PSS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. (1995) 333:1581–7. 10.1056/NEJM199512143332401
    1. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [ist-3]): a randomised controlled trial. Lancet. (2012) 379:2352–63. 10.1016/S0140-6736(12)60768-5
    1. Park MG, Oh EH, Kim BK, Park KP. Intravenous tissue plasminogen activator in acute branch atheromatous disease: does it prevent early neurological deterioration? J Clin Neurosci. (2016) 33:194–7. 10.1016/j.jocn.2016.04.011
    1. Deguchi I, Hayashi T, Kato Y, Nagoya H, Ohe Y, Fukuoka T, et al. . Treatment outcomes of tissue plasminogen activator infusion for branch atheromatous disease. J Stroke Cerebrovasc Dis. (2013) 22:e168–72. 10.1016/j.jstrokecerebrovasdis.2012.10.012
    1. Zhou L, Yao M, Peng B, Zhu Y, Ni J, Cui L. Atherosclerosis might be responsible for branch artery disease: evidence from white matter hyperintensity burden in acute isolated pontine infarction. Front Neurol. (2018) 9:840. 10.3389/fneur.2018.00840
    1. Liao S, Deng Z, Wang Y, Jiang T, Kang Z, Tan S, et al. . Different mechanisms of two subtypes of perforating artery infarct in the middle cerebral artery territory: a high-resolution magnetic resonance imaging study. Front Neurol. (2018) 9:657. 10.3389/fneur.2018.00657
    1. Petrone L, Nannoni S, Del Bene A, Palumbo V, Inzitari D. Branch atheromatous disease: a clinically meaningful, yet unproven concept. Cerebrovasc Dis. (2016) 41:87–95. 10.1159/000442577
    1. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. (2013) 369:11–9. 10.1056/NEJMoa1215340
    1. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. . Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. N Engl J Med. (2018) 379:215–5. 10.1056/NEJMoa1800410
    1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. . 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. (2018) 49:e46–e110. 10.1161/STR.0000000000000163
    1. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. (1988) 19:604–7. 10.1161/01.STR.19.5.604
    1. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ecass ii). Second European-Australasian acute stroke study investigators. Lancet. (1998) 352:1245–51. 10.1016/S0140-6736(98)08020-9
    1. Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology. (1989) 39:1246–50. 10.1212/WNL.39.9.1246
    1. Uchiyama S, Toyoda K, Kitagawa K, Okada Y, Ameriso S, Mundl H, et al. . Branch atheromatous disease diagnosed as embolic stroke of undetermined source: a sub-analysis of navigate esus. Int J Stroke. (2019) 14:915–22. 10.1177/1747493019852177
    1. Adams HP, Jr, Bendixen BH, Kappelle LJ, Biller J, sLove BB, et al. . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke. (1993) 24:35–41. 10.1161/01.STR.24.1.35
    1. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. (1991) 337:1521–6. 10.1016/0140-6736(91)93206-O
    1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. (1995) 333:1581–7.
    1. Suto Y, Nakayasu H, Maeda M, Kusumi M, Kowa H, Awaki E, et al. . Long-term prognosis of patients with large subcortical infarctions. Eur Neurol. (2009) 62:304–10. 10.1159/000235943
    1. Sun LL, Li ZH, Tang WX, Liu L, Chang FY, Zhang XB, et al. . High resolution magnetic resonance imaging in pathogenesis diagnosis of single lenticulostriate infarction with nonstenotic middle cerebral artery, a retrospective study. BMC Neurol. (2018) 18:51. 10.1186/s12883-018-1054-z
    1. Yamamoto Y, Nagakane Y, Makino M, Ohara T, Koizumi T, Makita N, et al. . Aggressive antiplatelet treatment for acute branch atheromatous disease type infarcts: a 12-year prospective study. Int J Stroke. (2014) 9:E8. 10.1111/ijs.12200
    1. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: A systematic review and meta-analysis. Circulation. (2017) 135:21–33. 10.1161/CIRCULATIONAHA.116.024913
    1. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between cyp2c19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. (2016) 316:70–8. 10.1001/jama.2016.8662
    1. Liao X, Wang Y, Pan Y, Wang C, Zhao X, Wang DZ, et al. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Stroke. (2014) 45:2354–8. 10.1161/STROKEAHA.114.005989
    1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. . Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. (2019) 50:e344–e418. 10.1161/STR.0000000000000211
    1. Kimura T, Tucker A, Sugimura T, Seki T, Fukuda S, Takeuchi S, et al. . Ultra-early combination antiplatelet therapy with cilostazol for the prevention of branch atheromatous disease: a multicenter prospective study. Cerebrovasc Dis Extra. (2016) 6:84–95. 10.1159/000450835
    1. Berberich A, Schneider C, Reiff T, Gumbinger C, Ringleb PA. Dual antiplatelet therapy improves functional outcome in patients with progressive lacunar strokes. Stroke. (2019) 50:1007–9. 10.1161/STROKEAHA.118.023789
    1. Charidimou A, Turc G, Oppenheim C, Yan S, Scheitz JF, Erdur H, et al. Microbleeds, cerebral hemorrhage, and functional outcome after stroke thrombolysis. Stroke. (2017) 48:2084–90. 10.1161/STROKEAHA.116.012992

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever